[Levamisole in the complex treatment of dysentery]. 1982

E M Usychenko, and V P Mashilov, and I V Rubtsov

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004405 Dysentery, Bacillary DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest). Shigellosis,Dysentery, Shiga bacillus,Dysentery, Shigella boydii,Dysentery, Shigella dysenteriae,Dysentery, Shigella dysenteriae type 1,Dysentery, Shigella flexneri,Dysentery, Shigella sonnei,Shigella Dysentery,Shigella Infection,Bacillary Dysentery,Dysenteries, Shigella,Dysenteries, Shigella boydii,Dysenteries, Shigella dysenteriae,Dysenteries, Shigella flexneri,Dysenteries, Shigella sonnei,Dysentery, Shigella,Infection, Shigella,Infections, Shigella,Shiga bacillus Dysentery,Shigella Dysenteries,Shigella Infections,Shigella boydii Dysenteries,Shigella boydii Dysentery,Shigella dysenteriae Dysenteries,Shigella dysenteriae Dysentery,Shigella flexneri Dysenteries,Shigella flexneri Dysentery,Shigella sonnei Dysenteries,Shigella sonnei Dysentery
D005664 Furazolidone A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514) Nifurazolidone,Furazol,Furazolidine,Furoxone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E M Usychenko, and V P Mashilov, and I V Rubtsov
December 1987, Vrachebnoe delo,
E M Usychenko, and V P Mashilov, and I V Rubtsov
August 1984, Voenno-meditsinskii zhurnal,
E M Usychenko, and V P Mashilov, and I V Rubtsov
May 1977, Sovetskaia meditsina,
E M Usychenko, and V P Mashilov, and I V Rubtsov
January 1986, Terapevticheskii arkhiv,
E M Usychenko, and V P Mashilov, and I V Rubtsov
November 1985, Akusherstvo i ginekologiia,
E M Usychenko, and V P Mashilov, and I V Rubtsov
October 1972, Klinicheskaia meditsina,
E M Usychenko, and V P Mashilov, and I V Rubtsov
January 1989, The British veterinary journal,
E M Usychenko, and V P Mashilov, and I V Rubtsov
May 1980, Vrachebnoe delo,
E M Usychenko, and V P Mashilov, and I V Rubtsov
April 1984, Vestnik dermatologii i venerologii,
E M Usychenko, and V P Mashilov, and I V Rubtsov
March 1986, Klinicheskaia meditsina,
Copied contents to your clipboard!